The Analysis Of Prognostic Factors Of Multiple Myeloma

Objective: A retrospective analysis of the relationship of clinical indicators andprognosis of multiple myeloma (MM).Materials and Methods: Collected from April2007to June2012, hospital Hematologyadmitted, diagnosed and patients with multiple myeloma, complete clinical data of143cases of clinical features, laboratory parameters and treatment programs using univariateand multivariate methodsanalysis of prognosis factors. Application SPSS17.0software forprocessing the data, with P <0.05as a significant difference was statistically significantusing the chi-square test, Kaplan-Meier survival analysis, CoX regression analysis showsthe relevant survival curves, analysis of data, observationthe prognosis.Results:143patients, male90cases,53cases of women with a median age of60yearsold (26to85years old), the median survival time was34months, and2-year survival ratewas65.3%, the5-year survival rate was32.6%. Univariate analysis found that age, thetotal number of bone marrow plasma cells, hemoglobin, platelet count, serum calciumconcentration, albumin, serum creatinine, β2-microglobulin, C-reactive protein, bonedisease classification, urine protein and urine Bence Jones protein and DurieSalmon (DS)staging is associated with prognosis. Cox multivariate analysis showed that C-reactiveprotein, β2-microglobulin, albumin, age, the total number of bone marrow plasma cells,serum creatinine is an independent prognostic factor. Bortezomib in combination withchemotherapy group TR rate and RR were higher than the conventional chemotherapygroup, the difference was statistically significant (P <0.05). Bortezomib in combinationwith chemotherapy group TR rate and RR were higher than the conventionalchemotherapy group, the difference was statistically significant (P <0.05).Conclusions: Age, the total number of bone marrow plasma cells, hemoglobin, plateletcount, serum calcium concentration, albumin, serum creatinine, β2-microglobulin,C-reactive protein, bone disease classification, urine protein, urine Bence Jones protein,DurieSalmon (DS) staging is associated with prognosis of multiple myeloma, Including C-reactive protein, β2-microglobulin, albumin, age, the total number of bone marrowplasma cells, serum creatinine were independent prognostic factors. Bortezomib incombination with combination chemotherapy regimens have a better effect on thetreatment of newly diagnosed and relapsed or refractory MM, a higher response rate andcomplete remission rate, compared with the conventional scheme.，However, treatmentoptions and the prognosis was not statistically significant.